Journal article icon

Journal article

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight

Abstract:

We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical principles; however, clinicians and professional bodies must take steps to ensu...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S2215-0366(17)30102-5

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Psychiatry
Role:
Author
More from this funder
Name:
Medical Research Council
Funding agency for:
Morgan, C
Grant:
MR L/023032/1
More from this funder
Name:
National Institutes for Health Research
Funding agency for:
McShane, R
More from this funder
Name:
Drugscience Charity
Funding agency for:
Schlag, A
More from this funder
Name:
Johnston & Johnston
Funding agency for:
Curran, V
Publisher:
Elsevier
Journal:
Lancet Psychiatry More from this journal
Volume:
4
Issue:
5
Pages:
419-426
Publication date:
2017-04-05
Acceptance date:
2016-11-16
DOI:
EISSN:
2215-0374
ISSN:
2215-0366
Pubs id:
pubs:665769
UUID:
uuid:1e2b2fc7-1a07-465f-af49-830ec98f2825
Local pid:
pubs:665769
Source identifiers:
665769
Deposit date:
2016-12-14

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP